Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.

about

Measuring FVIII activity of glycopegylated recombinant factor VIII, N8-GP, with commercially available one-stage clotting and chromogenic assay kits: a two-centre study.

Item

http://www.wikidata.org/entity/Q45864807

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@en

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@nl

type

Item

label

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@en

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@nl

prefLabel

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@en

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@nl

P1476

Measuring FVIII activity of gl ...... ssay kits: a two-centre study.

@en

P2093

A Bowyer

http://www.w3.org/2001/XMLSchema#string

A Hillarp

http://www.w3.org/2001/XMLSchema#string

M Ezban

http://www.w3.org/2001/XMLSchema#string

P Persson

http://www.w3.org/2001/XMLSchema#string

S Kitchen

http://www.w3.org/2001/XMLSchema#string

P2860

A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products.

Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis.

Novel products for haemostasis - current status.

Monitoring of modified factor VIII and IX products.

Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens.

Half-life extended factor VIII for the treatment of hemophilia A.

Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories.

In vivo recovery with products of very high purity--assay discrepancies.

Influence of phospholipids on the assessment of factor VIII activity.

P304

458-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/HAE.13168

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28198071

http://www.w3.org/2001/XMLSchema#string